Z: Osimertinib; 40 mg and 80 mg film-coated tablets; List A. I: TAGRISSO® is indicated for the adjuvant treatment after complete tumour resection in adult patients with non-squamous, non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) exon 19 deletions or exon 21 (L858R) substitution mutations, for the first-line treatment in adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as well as for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR T790M mutation who have progressed on or after EGFR TKI therapy. Dos: 80 mg once daily. Dose adjustment to 40 mg once daily possible. CI: Hypersensitivity to the active substance or to any of the excipients. Concomitant use of St. John’s Wort. W&P: Interstitial lung disease. QTc interval prolongation. LVEF and cardiomyopathy. Keratitis. Diarrhoea. Age and body weight. Developmental toxicity. IA: Strong CYP3A inducers. CYP3A4 substrates and transporters. ADRs: Very common: diarrhoea, stomatitis, rash, dry skin, paronychia, pruritus, platelet count decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased. Common: interstitial lung disease, blood creatinine increased, epistaxis, palmar-plantar erythrodysaesthesia syndrome, alopecia, urticaria. Uncommon, rare, very rare: see